The U.S. nuclear regulator is proposing to replace the 'As Low As Reasonably Achievable' (ALARA) radiation protection standard with objecti...

Nestle is set to eliminate all artificial food colorings globally by the end of 2026, a significant move by the major food producer. This i...

Despite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Nithin Kamath highlights patient retention challenges wi...

Wall Street's indices surged on Monday, lifted by a decrease in Middle East tensions and Comcast’s intention to divide into two separate fi...

Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like l...

Initial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...

Indian pharmaceutical giant Lupin Ltd has secured tentative approval from the US FDA for its generic enzalutamide tablets, a crucial treatm...

The launch follows marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for patients with locally advanced ...

A recent study reveals that taking a five-minute walking break every hour is the sweet spot for combating the health risks of prolonged sit...

Government's Minimum Import Price (MIP) initiative to boost domestic drug makers faces a slow start. Despite setting price thresholds for k...

Aurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...

Fixed dose combination banned full list: India has banned 16 fixed-dose combination drugs, including certain antibiotics and antispasmodics...

In a significant public health initiative, the ban on 16 fixed-dose drug combinations, including various antibiotics and topical formulatio...

India's free Human Papillomavirus vaccination drive is making significant progress. Nearly 50 lakh doses of the cervical cancer vaccine hav...

Rising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...

Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...